FibroDynamx is a drug discovery company with a proprietary platform for drug target identification based on regenerative healing models. There are no existing treatments on the market that prevent scarring, however medical need and pharmaceutical demand is considerable. Our first product (FD-001) is a protein-based drug that improves scarring and skin regeneration by 10-fold in pre-clinical models. We are raising $1.3M CAD to support IND-enabling studies.